Literature DB >> 6997330

Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients.

J G Gambertoglio, F Vincenti, N J Feduska, J Birnbaum, O Salvatierra, W J Amend.   

Abstract

Little information is available on the disposition of prednisolone in kidney transplant patients and whether correlations exist between the pharmacokinetics and therapeutic or toxic effects of this drug. The present study was designed to determine the pharmacokinetics of prednisolone in six noncushingoid and six cushingoid transplant recipients. The elimination half-lives were not significantly different in the noncushingoid and cushingoid patients (2.3 vs. 3.3 h). However, other pharmacokinetic parameters were significantly lower in the cushingoid group: plasma clearance (147 vs. 82 ml/min) and volume of distribution (32 vs. 20 liters). In addition, the availability of prednisolone after oral prednisone administration was considerably variable (overall range, 27-108%) and was not significantly different between the two groups. Thus, in kidney transplant patients it appears that the plasma clearance and volume of distribution of prednisolone may distinguish between noncushingoid and cushingoid patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6997330     DOI: 10.1210/jcem-51-3-561

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study.

Authors:  Anna Carmela P Sagcal-Gironella; Catherine M T Sherwin; Rommel G Tirona; Michael J Rieder; Hermine I Brunner; Alexander A Vinks
Journal:  Clin Ther       Date:  2011-10-07       Impact factor: 3.393

3.  Relative immunosuppressive potency of various corticosteroids measured in vitro.

Authors:  E Langhoff; J Ladefoged
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration.

Authors:  H Bergrem; P Grøttum; H E Rugstad
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients.

Authors:  F J Frey; W J Amend; F Lozada; B M Frey; N H Holford; L Z Benet
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 6.  Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review.

Authors:  J G Gambertoglio; W J Amend; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

7.  Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients.

Authors:  Katherine A Barraclough; Nicole M Isbel; Brett C McWhinney; Jacobus P J Ungerer; Gregory Medley; David W Johnson; Carmel M Hawley; Diana R Leary; Scott B Campbell; Christine E Staatz
Journal:  Eur J Clin Pharmacol       Date:  2011-06-09       Impact factor: 2.953

8.  Intra-individual consistency of prednisolone kinetics during long-term prednisone treatment.

Authors:  E Langhoff; H Flachs; J Ladefoged; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation.

Authors:  L Ost; I Björkhem; C von Bahr
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone.

Authors:  B M Frey; H J Schaad; F J Frey
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.